Aragona M
University of Rome La Sapienza, Faculty of Philosophy Rome, 00161 Rome, Italy.
Eat Weight Disord. 2007 Sep;12(3):e54-7. doi: 10.1007/BF03327643.
The aim of this case report was to examine the therapeutic benefit and tolerability of aripiprazole for psychotic symptoms in a case of anorexia nervosa comorbid with generalized epilepsy, chronic renal failure and Raynaud syndrome.
The patient had a chronic anorexia nervosa with psychotic symptoms, already treated with risperidone without efficacy, mainly because it was underdosed due to side-effects. She refused to take olanzapine (fear of weight gain) but accepted a treatment with aripiprazole. Aripiprazole 30 mg/day was associated with considerable improvement of SANS and SAPS (scale for the assessment of negative and positive symptoms) scores on hallucinations, delusions, aggressivity, abulia and asociality. Weight remained stable and no side-effects were reported.
These findings lend support to the possibility that aripiprazole may be useful and well tolerated in psychotic anorexia and in cases of comorbidity with epilepsy and/or renal failure. These data are preliminary and need to be confirmed in further controlled research.
本病例报告的目的是探讨阿立哌唑对神经性厌食症合并全身性癫痫、慢性肾衰竭和雷诺综合征患者精神症状的治疗效果及耐受性。
该患者患有伴有精神症状的慢性神经性厌食症,此前使用利培酮治疗无效,主要原因是因副作用而剂量不足。她拒绝服用奥氮平(担心体重增加),但接受了阿立哌唑治疗。每天30毫克阿立哌唑使阴性和阳性症状评定量表(SANS和SAPS)在幻觉、妄想、攻击性、意志缺失和社交障碍方面的评分有显著改善。体重保持稳定,且未报告有副作用。
这些发现支持了阿立哌唑在精神性厌食症以及合并癫痫和/或肾衰竭的病例中可能有效且耐受性良好的可能性。这些数据是初步的,需要在进一步的对照研究中得到证实。